Format

Send to

Choose Destination
Anticancer Res. 2015 Jan;35(1):517-21.

Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial.

Author information

1
3rd Medical Department with Haematology, Medical Oncology, Hemostaseology, Infectious Diseases, Rheumatology, Oncologic Centre, Salzburg Cancer Research Institute (SCRI) with the Laboratory of Immunological and Molecular Cancer Research (SCRI-LIMCR) and the Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT), Paracelsus Medical University Salzburg, Salzburg, Austria.
2
3rd Medical Department with Haematology and Medical Oncology, General Hospital Linz, Linz, Austria.
3
Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna)-LB-CTO and ACR-ITR VIEnna, Vienna, Austria.
4
Medical Department E with Oncology, General Hospital Rankweil, Rankweil, Austria.
5
Department of Gynaecology, Medical University Graz, Graz, Austria.
6
Ist Medical Department, General Hospital Elisabethinen Linz, Linz, Austria.
7
4th Medical Department, Hospital Wels-Grieskirchen, Grieskirchen, Austria.
8
Department of Medical Statistics and Informatics Medical University Innsbruck, Innsbruck, Austria.
9
3rd Medical Department with Haematology, Medical Oncology, Hemostaseology, Infectious Diseases, Rheumatology, Oncologic Centre, Salzburg Cancer Research Institute (SCRI) with the Laboratory of Immunological and Molecular Cancer Research (SCRI-LIMCR) and the Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT), Paracelsus Medical University Salzburg, Salzburg, Austria r.greil@salk.at.

Abstract

BACKGROUND:

Trastuzumab, one important treatment option for HER2-positive metastatic breast cancer (MBC) is limited by its cardiotoxic potential. Lapatinib and pegylated liposomal doxorubicin (PLD) represent a cardiosparing alternative that can cross the blood brain barrier. This is important, because one third of breast cancer patients develop brain metastases.

PATIENTS AND METHODS:

We included 24 patients with HER2-positive MBC progressing under trastuzumab. They received 1,250 mg lapatinib daily until progression plus PLD (40 mg/m(2)) every 4 weeks for maximal 6 cycles. The primary end-point was the overall response rate (ORR). Secondary end-points were progression-free survival (PFS), overall survival (OS), 1-year PFS and 1-year OS rates.

RESULTS:

ORR was 54%. Median PFS was 5.8 and median OS 23.3 months. The one-year PFS rate was 27% and 1-year OS rate 76%.

CONCLUSION:

Lapatinib-plus-PLD is active and safe in HER2-positive MBC, especially suitable for patients with cardiological risk or brain metastases.

KEYWORDS:

Her2-positive; Metastatic breast cancer; lapatinib; pegylated liposomal doxorubicin

PMID:
25550597
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center